二肽基肽酶I抑制剂的研究进展  

Research Progress of Dipeptidyl Peptidase I Inhibitors

作　　者：吴丹 陈星 范高福[1] 刘修树[1] WU Dan;CHEN Xing;FAN Gaofu;LIU Xiushu(School of Bioengineering,Hefei Vocational and Technical College,Hefei 238000,Anhui,China;Key Laboratory of Population Health Across Life Cycle,School of Public Health,Anhui Medical University,Hefei 230032,Anhui,China)

机构地区：[1]合肥职业技术学院生物工程学院,安徽合肥238000 [2]安徽医科大学公共卫生学院人口健康与优生安徽省重点实验室,安徽合肥230032

出　　处：《汕头大学学报（自然科学版）》2024年第2期45-58,共14页Journal of Shantou University：Natural Science Edition

基　　金：安徽省高校自然科学研究重大项目(KJ2021ZD0159);安徽省高校学科(专业)拔尖人才学术资助项目(gxbjZD2021116);合肥职业技术学院校级重点项目(2021KJA07);安徽省高校自然科学重点项目(KJ2021A1388)。

摘　　要：中性粒细胞是先天免疫系统的重要组成部分,其功能失调和多种疾病密切相关.二肽基肽酶I是一种溶酶体半胱氨酸蛋白酶,介导中性粒细胞相关炎症过程,在多种炎症性疾病中发挥关键作用,因此成为炎症性疾病治疗药物开发的新颖靶点.文章从基于经验的药物设计、基于靶标的理性设计和靶标设计位点新选择三个方面综述了二肽基肽酶I抑制剂的研究进展,旨在为开发新型高效、低毒的二肽基肽酶I抑制剂提供参考.Neutrophil is an important part of the innate immune system,and the dysfunction of neutrophil is closely related to many diseases.Dipeptidyl peptidase I is a lysosomal cysteine protease that mediates neutrophil associated inflammatory processes.Dipeptidyl peptidase I plays a key role in various inflammatory diseases,and has become a novel target for the development of therapeutic drug for inflammatory diseases.In this paper,the research progress of dipeptidyl peptidase I inhibitors is summarized from three aspects:experience-based drug design,target-based rational design,and new selection of target design site,aiming to provide references for the development of novel high-efficiency,low-toxicity dipeptidyl peptidase I inhibitors.

关 键 词：二肽基肽酶I 抑制剂 中性粒细胞 炎症性疾病 

分 类 号：R914.2[医药卫生—药物化学]